Berlin, 31.03.2017/08:00 – M1 Kliniken AG, ISIN: DE000A0STSQ8, announces its preliminary IFRS result for 2016.
- During the reporting period the preliminary annual net income was €5,455,893.52, with earnings per share of €0.36 (annual net income for previous year: €6,631,000, €0.44 earnings per share).
- The dividend should be 30 cents per share as in the previous year.
- Equity increased to €30,705,804.39 (previous year: €29,750,000).
- The equity ratio increased from 90% to 94%.
In 2016 the Frankfurt Stock Exchange listed M1 Kliniken AG again reported a successful fiscal year. The company increased its sales to €36,546,000.
The clinic in Berlin was expanded to six operating rooms and 35 patient beds. During the reporting period 13 M1 specialist centres were available nationwide following additional openings. The M1 concept of offering top quality and affordable access to aesthetic medicine is well received by clients; as a result M1 has ascended to become a leading provider in this area.
M1 Group uses the economies of scale to make further optimisations in product selection, development and marketing of branded products to doctors, pharmacists and wholesalers.
The Board will recommend a dividend of 30 cents per share (previous year: 30 cents per share) to the shareholders’ meeting.
In 2017 M1 Group will continue to invest in the quality of services. This includes digitisation, further training for specialist personnel and the continuous development of quality standards. The company aims to increase sales by 20%.
Current opportunities for growth will be realised by expanding existing sites and establishing new sites in Germany and Europe.